Intranasal Versus Intravenous Fentanyl For Procedural Analgesia in Preterm Neonates

NCT ID: NCT07190625

Last Updated: 2025-10-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-24

Study Completion Date

2026-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pain in neonatal life has profound long-term developmental impacts, so pain control is crucial. The intranasal (IN) route is a minimally invasive method for rapidly delivering fentanyl to provide short-term analgesia and sedation in adults and pediatrics, but few data exist about its use in neonates. Meanwhile, intravenous fentanyl is widely used in sedation and pain management.

Using intranasal fentanyl as an analgesic in preterm neonates may provide a rapid, effective, noninvasive route for administration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is to evaluate the effect of intranasal fentanyl versus the intravenous route for procedural pain management in preterm neonates as assessed by pain scoring system before and after the procedure.

Enrolled neonates will be allocated randomly to one of the three groups during painful procedure, using single blinded method, as scoring will occur by a different physician than the researcher.

Atomizer group: will receive intranasal fentanyl (@fentanyl hamein 50 mcg/1 ml, manufactured by Sunny Pharmaceutical) using a nasal atomizer; the dose of INF is 1.5 µg/kg/dose.

Direct nasal group: will receive intranasal fentanyl directly installed into the nostrils with the same dose.

Typically, one dose is given during the procedure; after 5 minutes, a second dose could be administered based on the clinical assessment (maximum two doses per procedure), with reassessment of the pain score.

o Intravenous group: will receive intravenous fentanyl with a dose of 1 μg/kg as the standard of care.

All of the following data will be obtained:

Full history taking: antenatal, natal, and postnatal history Gestational age will be estimated using the date of the last menstrual period and confirmed by the new Ballard scoring system.

Full clinical examination: including general, cardiopulmonary, abdominal, and neurological examinations and anthropometric measurements.

Type of procedure done to the patient, number of attempts if more than once, and number of intranasal fentanyl doses needed.

Type of respiratory support at the time of intranasal fentanyl administration.

Effectiveness of intranasal fentanyl will be assessed using:

Premature Infant Pain Profile (PIPP) scale The pre-procedure PIPP scale will be recorded just before administration of the first dose of IN fentanyl and commencement of the painful procedure, while the post-procedure PIPP score will be recorded within 5 minutes of fentanyl administration.

PIPP scores range from 0 to 21. A PIPP score of 0-6 suggests minimal or no pain, 7-12 indicates moderate pain, and a score ≥ 13 is interpreted as severe pain.

Physiological parameters of heart rate, respiratory rate, oxygen saturation, blood pressure, and fraction of inspired oxygen (FiO2) at baseline (just before fentanyl administration) and at pre-specified intervals (15, 30, 45, and 60 min) after fentanyl use.

Monitor adverse events after fentanyl use, such as apnea (cessation of breathing for \>20 s), bradycardia (heart rate \< 100 beats/minute), desaturation (oxygen saturation \< 80%) , and chest wall rigidity associated with laryngospasm for 60 min after IN fentanyl administration. Local effects include nasal discomfort and irritation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Procedural Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intravenous group

this group of neonates will recieve intravenous fentanyl during procedure

Group Type ACTIVE_COMPARATOR

fentanyl intravenous

Intervention Type DRUG

giving intravenous fentanyl

direct intranasal group

this group of neonates will recieve direct intranasal fentanyl during procedure

Group Type ACTIVE_COMPARATOR

fentanyl intranasal direct

Intervention Type DRUG

giving intranasal fentanyl directly into nostrils

nasal atomizer group

this group of neonates will recieve intranasal fentanyl with atomizer during procedure

Group Type ACTIVE_COMPARATOR

Fentanyl intranasal using atomizer

Intervention Type DRUG

giving intranasal fentanyl using nasal atomizer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fentanyl intravenous

giving intravenous fentanyl

Intervention Type DRUG

Fentanyl intranasal using atomizer

giving intranasal fentanyl using nasal atomizer

Intervention Type DRUG

fentanyl intranasal direct

giving intranasal fentanyl directly into nostrils

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Preterm neonates with gestational age between 28 and 36 weeks gestation.
* Undergoing painful procedures such as central venous access insertion, elective endotracheal intubation, and lumbar puncture.

Exclusion Criteria

* known contraindications for fentanyl use, such as fentanyl hypersensitivity and liver failure.
* Known contraindication for intranasal administration of drugs (choanal atresia, nasal mucosal erosion, and epistaxis)
* Post-surgical patients.
* Patients sedated by fentanyl infusion / midazolam infusion.
* Evidence of neurological disease with disturbed conscious level, such as intraventricular hemorrhage grade III or IV, hypoxic ischemic encephalopathy, or inborn error of metabolism.
Maximum Eligible Age

28 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Passant Fahmy, M.Sc

Role: PRINCIPAL_INVESTIGATOR

Assisstant lecturer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ain Shams University

Cairo, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Passant Osama Fahmy, M.Sc

Role: CONTACT

01066724641

Rabab Gameel Allam, MD

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FMASU MD342/2023

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nonpharmacological Pain Management in Neonates
NCT06155825 NOT_YET_RECRUITING NA
The Use of Ketorolac in Surgical Neonates
NCT01667120 WITHDRAWN PHASE2